Second chances for secondary AML.
作者信息
Appelbaum Jacob S, Appelbaum Frederick R, Percival Mary-Elizabeth
机构信息
Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, WA.
Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.
出版信息
Blood Adv. 2024 Aug 13;8(15):4221-4222. doi: 10.1182/bloodadvances.2024013318.
Abstract
摘要
相似文献
1
Second chances for secondary AML.
Blood Adv. 2024 Aug 13;8(15):4221-4222. doi: 10.1182/bloodadvances.2024013318.
2
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
Crit Rev Oncol Hematol. 2019 Jun;138:6-13. doi: 10.1016/j.critrevonc.2019.03.003. Epub 2019 Mar 16.
3
Acute Myeloid Leukemia Diagnosed 5 Years after Adult T-Cell Leukemia/Lymphoma.
J Clin Exp Hematop. 2015;55(1):29-31. doi: 10.3960/jslrt.55.29.
4
Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
Ann Hematol. 2017 May;96(5):719-724. doi: 10.1007/s00277-017-2933-x. Epub 2017 Feb 1.
5
Identification of novel gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review.
Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). doi: 10.1101/mcs.a002204. Print 2018 Apr.
6
Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML.
Pediatr Blood Cancer. 2006 Sep;47(3):345-6. doi: 10.1002/pbc.20832.
7
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Blood Cancer J. 2019 Jan 16;9(2):7. doi: 10.1038/s41408-019-0170-3.
8
Secondary acute myeloid leukemia arising early after cyclophosphamide treatment.
Int J Clin Pharm. 2015 Apr;37(2):289-91. doi: 10.1007/s11096-015-0069-4. Epub 2015 Jan 23.
9
Lineage switch of B-lymphoblastic leukemia into acute myeloid leukemia with residual lymphoblasts in a patient with previous breast cancer.
Int J Lab Hematol. 2021 Aug;43(4):O197-O199. doi: 10.1111/ijlh.13510. Epub 2021 Mar 14.
10
Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.
Cancer Med. 2019 Jul;8(8):3846-3854. doi: 10.1002/cam4.2020. Epub 2019 Jun 7.
本文引用的文献
1
Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT.
Blood Adv. 2024 Aug 13;8(15):4223-4233. doi: 10.1182/bloodadvances.2024012798.
2
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4.
3
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
Cancers (Basel). 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734.
4
Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.
J Clin Oncol. 2022 Apr 10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. Epub 2022 Jan 10.
5
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
6
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24.
7
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Blood Adv. 2019 Jun 25;3(12):1826-1836. doi: 10.1182/bloodadvances.2019000050.
8
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.
9
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.
Biol Blood Marrow Transplant. 2015 Mar;21(3):559-64. doi: 10.1016/j.bbmt.2014.10.025. Epub 2014 Dec 20.
10
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
J Clin Oncol. 2014 Jun 20;32(18):1919-26. doi: 10.1200/JCO.2013.52.8562. Epub 2014 May 19.
Zotero 插件